1-4 of 4
Kari Anne Sveen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes

Kari Anne Sveen, Kristine Bech Holte, Mona Svanteson, Kristian F. Hanssen, Jan Nilsson, Eva Bengtsson, Tore Julsrud Berg
Journal: Diabetes Care
Diabetes Care 2021;44(6):1402–1409
https://doi.org/10.2337/dc20-2089
Published: 15 April 2021
View article titled, Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes
Open the PDF for Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes in another window
Journal Articles

Small- and Large-Fiber Neuropathy After 40 Years of Type 1 Diabetes: Associations with glycemic control and advanced protein glycation: the Oslo Study

Kari Anne Sveen, MD, Bassam Karimé, MD, Ellen Jørum, MD, Svein Ivar Mellgren, MD, Morten Wang Fagerland, PHD, Vincent M. Monnier, MD, Knut Dahl-Jørgensen, MD, Kristian F. Hanssen, MD
Journal: Diabetes Care
Diabetes Care 2013;36(11):3712–3717
https://doi.org/10.2337/dc13-0788
Published: 15 October 2013
View article titled, Small- and Large-Fiber Neuropathy After 40 Years of Type 1 Diabetes: <subtitle>Associations with glycemic control and advanced protein glycation: the Oslo Study</subtitle>
Open the PDF for Small- and Large-Fiber Neuropathy After 40 Years of Type 1 Diabetes: <subtitle>Associations with glycemic control and advanced protein glycation: the Oslo Study</subtitle> in another window
Includes: Supplementary data
Journal Articles

Response to Comment on: Fraser et al. The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes Care 2012;35:1095–1097

David A. Fraser, PHD, Lien M. Diep, MSC, Inger Anette Hovden, MD, PHD, Kristian B. Nilsen, MD, PHD, Kari Anne Sveen, MD, Ingebjørg Seljeflot, PHD, Kristian F. Hanssen, MD, PHD
Journal: Diabetes Care
Diabetes Care 2012;35(11):e80
https://doi.org/10.2337/dc12-1124
Published: 13 October 2012
View article titled, Response to Comment on: Fraser et al. The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes Care 2012;35:1095–1097
Open the PDF for Response to Comment on: Fraser et al. The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes Care 2012;35:1095–1097 in another window
Journal Articles

The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-month, double-blind, randomized, placebo-controlled trial

David A. Fraser, PHD, Lien M. Diep, MSC, Inger Anette Hovden, MD, Kristian B. Nilsen, MD, Kari Anne Sveen, MD, Ingebjørg Seljeflot, PHD, Kristian F. Hanssen, MD
Journal: Diabetes Care
Diabetes Care 2012;35(5):1095–1097
https://doi.org/10.2337/dc11-1895
Published: 11 April 2012
View article titled, The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: <subtitle>A 24-month, double-blind, randomized, placebo-controlled trial</subtitle>
Open the PDF for The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: <subtitle>A 24-month, double-blind, randomized, placebo-controlled trial</subtitle> in another window
Includes: Supplementary data